SEC Company Response from CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869) (CAPR) — Nov 6, 2007

CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869)
Date: Nov. 6, 2007 · CIK: 0001133869 · Accession: 0001144204-07-058428

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-146843

Date

Nov. 6, 2007

Author

Director

Form

CORRESP

Company

CAPRICOR THERAPEUTICS, INC. (CAPR) (CIK 0001133869)

Letter

Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Nile Therapeutics, Inc. Registration Statement on Form SB-2 (File No. 333-146843)

Dear Mr. Riedler:

Nile Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effectiveness of the Company’s Registration Statement on Form SB-2 for up to 9,860,376 shares of common stock, par value $0.001 per share, of the Company, be accelerated to 4:30 p.m., November 6, 2007, or as soon thereafter as is practicable.

In furnishing this letter, the Company acknowledges that:

▪

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

▪

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

▪

the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very
truly
yours,
Nile Therapeutics, Inc.

Show Raw Text

CORRESP
1
filename1.htm

    November
      6, 2007

    Mr.
      Jeffrey Riedler

    Assistant
      Director

    Securities
      and Exchange Commission

    Division
      of Corporate Finance

    Mail
      Stop
      6010

    Washington,
      D.C. 20549

    Nile
      Therapeutics, Inc.

    Registration
      Statement on Form SB-2

    (File
      No. 333-146843)

    Dear
      Mr.
      Riedler:

    Nile
      Therapeutics, Inc., a Delaware corporation (the “Company”),
      hereby requests that the effectiveness of the Company’s Registration Statement
      on Form SB-2 for up to 9,860,376 shares of common stock, par value $0.001 per
      share, of the Company, be accelerated to 4:30 p.m., November 6, 2007, or as
      soon
      thereafter as is practicable.

    In
      furnishing this letter, the Company acknowledges that:

              ▪

              should
                the Commission or the staff, acting pursuant to delegated authority,
                declare the filing effective, it does not foreclose the Commission
                from
                taking any action with respect to the
                filing;

              ▪

              the
                action of the Commission or the staff, acting pursuant to delegated
                authority, in declaring the filing effective, does not relieve the
                Company
                from its full responsibility for the adequacy and accuracy of the
                disclosure in the filing; and

              ▪

              the
                Company may not assert this action as a defense in any proceeding
                initiated by the Commission or any person under the federal securities
                laws of the United States.

            Very
              truly
              yours,

            Nile Therapeutics, Inc.

            By:
            /s/ Peter
              M.
              Strumph

              Name:
              Peter M. Strumph

            Title:
              Chief Executive Officer

SecProbe.io